Literature DB >> 12818961

Peripheral antihyperalgesic and analgesic actions of ketamine and amitriptyline in a model of mild thermal injury in the rat.

Mark Oatway1, Allison Reid, Jana Sawynok.   

Abstract

UNLABELLED: In this study, we examined antihyperalgesic and analgesic actions after local peripheral administration of ketamine and amitriptyline in a rat model of mild thermal injury. Exposure of the hindpaw to 52 degrees C for 45 s under anesthesia produced a subsequent thermal hyperalgesia lasting at least 2 h. The local peripheral administration of ketamine (100-1000 nmol) 15 min before the thermal injury produced an antihyperalgesic effect when injected into the ipsilateral paw, whereas amitriptyline produced both antihyperalgesic (300 nmol) and analgesic (1000 nmol) effects. Administered after the thermal injury, ketamine had no effect, whereas amitriptyline retained its analgesic but not its antihyperalgesic effect. Amitriptyline (300 and 1000 nmol) produced an analgesic action when administered into the normal nonsensitized hindpaw. Both drugs increase paw volume, particularly at larger doses; biogenic amines are not involved in the action of amitriptyline, as was shown previously for ketamine. These results indicate that (a) ketamine produces antihyperalgesia, but not analgesia, when administered locally with a mild thermal injury model; (b) amitriptyline produces both antihyperalgesia and analgesia when administered locally; and (c) the increase in paw volume produced by these drugs occurs by different mechanisms. IMPLICATIONS: This study examines the pain-relieving properties of the local peripheral administration of ketamine and amitriptyline, two drugs in current clinical use, in a thermal injury model of hyperalgesia and demonstrates both antihyperalgesic and analgesic properties. These observations provide support for their potential use as local (e.g., topical) analgesics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818961     DOI: 10.1213/01.ane.0000067406.52093.bf

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats.

Authors:  Jing Wang; Yossef Goffer; Duo Xu; David S Tukey; D B Shamir; Sarah E Eberle; Anthony H Zou; Thomas J J Blanck; Edward B Ziff
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

Review 2.  Antidepressants as analgesics.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat.

Authors:  Liliane J Dableh; Kiran Yashpal; Joseph Rochford; James L Henry
Journal:  Eur J Pharmacol       Date:  2004-12-28       Impact factor: 4.432

4.  A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception.

Authors:  F S Hall; J M Schwarzbaum; M T G Perona; J S Templin; M G Caron; K-P Lesch; D L Murphy; G R Uhl
Journal:  Neuroscience       Date:  2010-12-01       Impact factor: 3.590

5.  Antinociceptive and antidepressive efficacies of the combined ineffective doses of S-ketamine and URB597.

Authors:  Mohaddeseh Ebrahimi-Ghiri; Faezeh Shahini; Fatemeh Khakpai; Mohammad-Reza Zarrindast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-06-27       Impact factor: 3.000

6.  Antinociception occurs with a reversal in alpha 2-adrenoceptor regulation of TNF production by peripheral monocytes/macrophages from pro- to anti-inflammatory.

Authors:  Reeteka Sud; Robert N Spengler; Nader D Nader; Tracey A Ignatowski
Journal:  Eur J Pharmacol       Date:  2008-04-24       Impact factor: 4.432

7.  Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target.

Authors:  Kathleen Yin; Jennifer R Deuis; Richard J Lewis; Irina Vetter
Journal:  Mol Pain       Date:  2016-08-28       Impact factor: 3.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.